How Adagrasib works

The action process of Adagrasib (Adagrasib) mainly involves the specific inhibition of KRAS G12C mutation, KRAS G12Cis a mutated form of the RAS family geneKRAS and is closely related to the development and growth of various cancers. Adagrasibis designed as a KRAS G12C inhibitor designed to interfere with the growth and spread of cancer cells by specifically interfering with the activity of this mutated gene.

This process can be divided into several key steps:

1.Selective binding: Adagrasib selectively binds to specific sites of KRAS G12C protein through its chemical structure. This binding is highly specific and targets the KRAS G12C mutation, thereby reducing the impact on normal cells.

2.Inhibits the activity ofKRAS G12C: Once combined with KRAS G12C, adagrasib will affect the activity of this mutated gene. KRAS is a key regulator in cell signaling, and its overactivation is closely related to the development of cancer. Adagrasib blocks abnormal signaling pathways by inhibiting KRAS G12C activity.

3.Blocks the proliferation and survival of cancer cells: Inhibition of KRAS G12C leads to the interruption of signaling pathways within cancer cells, hindering the proliferation and survival of cancer cells. This effect helps limit the spread and growth of cancer cells, thereby inhibiting cancer development.

4.Direct the immune system to attack cancer cells: Some studies have shown that KRAS G12CThe use of inhibitors may activate the immune system, making it easier to recognize and attack cancer cells. This immunomodulatory effect helps to improve the therapeutic effect and enhance the patient's immune response to a certain extent.

Adagrasib is not currently available in the country, so patients cannot purchase it domestically and can only purchase adagrasib through overseas channels. Abroad, there is only the original American drug adagrasib, and the price is very high, as high as about 190,000 yuan.